Identifying priority medicines policy issues for New Zealand

a general inductive study

Zaheer-Ud-Din Babar, Susan Francis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives To identify priority medicines policy issues for New Zealand.

Setting Stakeholders from a broad range of healthcare and policy institutions including primary, secondary and tertiary care.

Participants Exploratory, semistructured interviews were conducted with 20 stakeholders throughout New Zealand.

Primary and secondary outcome measures The interviews were digitally recorded, transcribed and coded into INVIVO 10, then compared and grouped for similarity of theme. Perceptions, experiences and opinions regarding New Zealand's medicines policy issues were recorded.

Results A large proportion of stakeholders appeared to be unaware of New Zealand's (NZ) medicines policy. In general, the policy was considered to offer consistency to guide decision-making. In the context of Pharmaceutical Management Agency's (PHARMAC's) fixed budget for procuring and subsidising medicines, there was reasonable satisfaction with the range of medicines available—rare disorder medicines being the clear exception. Concerns raised were by whom and how decisions are made and whether desired health outcomes are being measured. Other concerns included inconsistencies in evidence and across health technologies. Despite attempts to improve the situation, lower socioeconomic groups (including rural residents) Māori and Pacific ethnicities and people with rare disorders face challenges with regards to accessing medicines. Other barriers include, convenience to and affordability of prescribers and the increase of prescription fees from NZ$3 to NZ$5. Concerns related to the PHARMAC of New Zealand included: a constraining budget; non-transparency of in-house analysis; lack of consistency in recommendations between the Pharmacology and Therapeutics Advisory Committee. Constraints and inefficiencies also exist in the submission process to access high-cost medicines.

Conclusions The results suggest reasonable satisfaction with the availability of subsidised medicines. However, some of the major challenges include access to medicines in vulnerable groups, increasing costs and demand for new medicines, access to prescribers, budgetary constraints, cultural and health literacy, patient affordability and evidence requirement for gaining subsidy for medicines.
Original languageEnglish
Article numbere004415
Number of pages12
JournalBMJ Open
Volume4
DOIs
Publication statusPublished - 28 May 2014
Externally publishedYes

Fingerprint

New Zealand
Budgets
Prescription Fees
Pharmacy and Therapeutics Committee
Interviews
Health Literacy
Morus
Costs and Cost Analysis
Secondary Care
Biomedical Technology
Advisory Committees
Tertiary Healthcare
Pharmaceutical Preparations
Primary Health Care
Decision Making
Outcome Assessment (Health Care)
Pharmacology
Delivery of Health Care
Health

Cite this

@article{83c42e992b1b4adc92f67ae6fc091a4d,
title = "Identifying priority medicines policy issues for New Zealand: a general inductive study",
abstract = "Objectives To identify priority medicines policy issues for New Zealand.Setting Stakeholders from a broad range of healthcare and policy institutions including primary, secondary and tertiary care.Participants Exploratory, semistructured interviews were conducted with 20 stakeholders throughout New Zealand.Primary and secondary outcome measures The interviews were digitally recorded, transcribed and coded into INVIVO 10, then compared and grouped for similarity of theme. Perceptions, experiences and opinions regarding New Zealand's medicines policy issues were recorded.Results A large proportion of stakeholders appeared to be unaware of New Zealand's (NZ) medicines policy. In general, the policy was considered to offer consistency to guide decision-making. In the context of Pharmaceutical Management Agency's (PHARMAC's) fixed budget for procuring and subsidising medicines, there was reasonable satisfaction with the range of medicines available—rare disorder medicines being the clear exception. Concerns raised were by whom and how decisions are made and whether desired health outcomes are being measured. Other concerns included inconsistencies in evidence and across health technologies. Despite attempts to improve the situation, lower socioeconomic groups (including rural residents) Māori and Pacific ethnicities and people with rare disorders face challenges with regards to accessing medicines. Other barriers include, convenience to and affordability of prescribers and the increase of prescription fees from NZ$3 to NZ$5. Concerns related to the PHARMAC of New Zealand included: a constraining budget; non-transparency of in-house analysis; lack of consistency in recommendations between the Pharmacology and Therapeutics Advisory Committee. Constraints and inefficiencies also exist in the submission process to access high-cost medicines.Conclusions The results suggest reasonable satisfaction with the availability of subsidised medicines. However, some of the major challenges include access to medicines in vulnerable groups, increasing costs and demand for new medicines, access to prescribers, budgetary constraints, cultural and health literacy, patient affordability and evidence requirement for gaining subsidy for medicines.",
author = "Zaheer-Ud-Din Babar and Susan Francis",
year = "2014",
month = "5",
day = "28",
doi = "10.1136/bmjopen-2013-004415",
language = "English",
volume = "4",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "British Medical Journal Publishing Group",

}

Identifying priority medicines policy issues for New Zealand : a general inductive study. / Babar, Zaheer-Ud-Din; Francis, Susan.

In: BMJ Open, Vol. 4, e004415, 28.05.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identifying priority medicines policy issues for New Zealand

T2 - a general inductive study

AU - Babar, Zaheer-Ud-Din

AU - Francis, Susan

PY - 2014/5/28

Y1 - 2014/5/28

N2 - Objectives To identify priority medicines policy issues for New Zealand.Setting Stakeholders from a broad range of healthcare and policy institutions including primary, secondary and tertiary care.Participants Exploratory, semistructured interviews were conducted with 20 stakeholders throughout New Zealand.Primary and secondary outcome measures The interviews were digitally recorded, transcribed and coded into INVIVO 10, then compared and grouped for similarity of theme. Perceptions, experiences and opinions regarding New Zealand's medicines policy issues were recorded.Results A large proportion of stakeholders appeared to be unaware of New Zealand's (NZ) medicines policy. In general, the policy was considered to offer consistency to guide decision-making. In the context of Pharmaceutical Management Agency's (PHARMAC's) fixed budget for procuring and subsidising medicines, there was reasonable satisfaction with the range of medicines available—rare disorder medicines being the clear exception. Concerns raised were by whom and how decisions are made and whether desired health outcomes are being measured. Other concerns included inconsistencies in evidence and across health technologies. Despite attempts to improve the situation, lower socioeconomic groups (including rural residents) Māori and Pacific ethnicities and people with rare disorders face challenges with regards to accessing medicines. Other barriers include, convenience to and affordability of prescribers and the increase of prescription fees from NZ$3 to NZ$5. Concerns related to the PHARMAC of New Zealand included: a constraining budget; non-transparency of in-house analysis; lack of consistency in recommendations between the Pharmacology and Therapeutics Advisory Committee. Constraints and inefficiencies also exist in the submission process to access high-cost medicines.Conclusions The results suggest reasonable satisfaction with the availability of subsidised medicines. However, some of the major challenges include access to medicines in vulnerable groups, increasing costs and demand for new medicines, access to prescribers, budgetary constraints, cultural and health literacy, patient affordability and evidence requirement for gaining subsidy for medicines.

AB - Objectives To identify priority medicines policy issues for New Zealand.Setting Stakeholders from a broad range of healthcare and policy institutions including primary, secondary and tertiary care.Participants Exploratory, semistructured interviews were conducted with 20 stakeholders throughout New Zealand.Primary and secondary outcome measures The interviews were digitally recorded, transcribed and coded into INVIVO 10, then compared and grouped for similarity of theme. Perceptions, experiences and opinions regarding New Zealand's medicines policy issues were recorded.Results A large proportion of stakeholders appeared to be unaware of New Zealand's (NZ) medicines policy. In general, the policy was considered to offer consistency to guide decision-making. In the context of Pharmaceutical Management Agency's (PHARMAC's) fixed budget for procuring and subsidising medicines, there was reasonable satisfaction with the range of medicines available—rare disorder medicines being the clear exception. Concerns raised were by whom and how decisions are made and whether desired health outcomes are being measured. Other concerns included inconsistencies in evidence and across health technologies. Despite attempts to improve the situation, lower socioeconomic groups (including rural residents) Māori and Pacific ethnicities and people with rare disorders face challenges with regards to accessing medicines. Other barriers include, convenience to and affordability of prescribers and the increase of prescription fees from NZ$3 to NZ$5. Concerns related to the PHARMAC of New Zealand included: a constraining budget; non-transparency of in-house analysis; lack of consistency in recommendations between the Pharmacology and Therapeutics Advisory Committee. Constraints and inefficiencies also exist in the submission process to access high-cost medicines.Conclusions The results suggest reasonable satisfaction with the availability of subsidised medicines. However, some of the major challenges include access to medicines in vulnerable groups, increasing costs and demand for new medicines, access to prescribers, budgetary constraints, cultural and health literacy, patient affordability and evidence requirement for gaining subsidy for medicines.

U2 - 10.1136/bmjopen-2013-004415

DO - 10.1136/bmjopen-2013-004415

M3 - Article

VL - 4

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

M1 - e004415

ER -